MRIAD: A Pre-clinical Prevalence Study on Alzheimer’s Disease Prediction Through Machine Learning Classifiers

Alzheimer’s disease (AD) is a neurological illness that worsens with time. The aged population has expanded in recent years, as has the prevalence of geriatric illnesses. There is no cure, but early detection and proper treatment allow sufferers to live normal lives. Furthermore, people with this disease’s immune systems steadily degenerate, resulting in a wide range of severe disorders. Neuroimaging Data from magnetic resonance imaging (MRI) is utilized to identify and detect the disease as early as possible. The data is derived from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) collection of 266 people with 177 structural brain MRI imaging, DTI, and PET data for intermediate disease diagnosis. When neuropsychological and cognitive data are integrated, the study found that ML can aid in the identification of preclinical Alzheimer’s disease. Our primary objective is to develop a model that is reliable, simple, and rapid for diagnosing preclinical Alzheimer’s disease. According to our findings (MRIAD), the Logistic Regression (LR) model has the best accuracy and classification prediction of about 98%. The ML model is also developed in the paper. This article profoundly, describes the possibility to getting into Alzheimer’s disease (AD) information from the pre-clinical or non-preclinical trial datasets using Machine Learning Classifier (ML) approaches.